6533-00-2
6533-00-2 結(jié)構(gòu)式
基本信息
DL-甲基炔諾酮
炔諾孕酮
左炔諾孕酮
高諾酮
藥典標(biāo)準(zhǔn)品
左炔孕酮
(+/-)-13-ETHYL-17ALPHA-HYDROXY-18,19-DINORPREGN-4-EN-20-YN-3-ONE
17-ALPHA-ETHYNYL-18-HOMO-19-NORTESTOSTERONE
18,19-DINOR-13-BETA-ETHYL-17-BETA-HYDROXY-4-PREGNEN-20-YN-3-ONE
18,19-DINOR-4-PREGNEN-20-YN-3-ONE
4-ESTREN-17-ALPHA-ETHYNYL-18-HOMO-17-BETA-OL-3-ONE(+/-)
4-GONEN-13BETA-ETHYL-17ALPHA-ETHYNYL-17BETA-OL-3-ONE
4-PREGNEN-13BETA-ETHYL-18,19-DINOR 17BETA-OL-3-ONE-20-YNE
d(-)-13beta-ethyl-17alpha-ethynyl-17beta-hydroxygon-4-en-3-one
dl-13b-ethyl-17a-ethynyl-17b-hydroxygon-4-en-3-one
D(-)-NORGESTREL
D-NORGESTREL
LEVONORGESTREL
NORGESTREL
NORGESTREL(LEVO)
NORPLANT
OVRETTE(R)
(+-)-13-ethyl-17-hydroxy-18,19-dinor-17-alpha-pregn-4-en-20-yn-3-one
13-ethyl-17-hydroxy-19-dinorpregn-4-en-20-yn-3-on(17-alpha)-(+-)-1
alpha-norgestrel
物理化學(xué)性質(zhì)
安全數(shù)據(jù)
常見問題列表
Norgestrel (20 μM; 24 hours; 661W cells) treatment significantly increases cellular viability after serum deprivation and so it is demonstrated that Norgestrel is neuroprotective to stressed 661W cells.
Norgestrel (20 μM; 24 hours; 661W cells) treatment decreases apoptotic induced cleavage of PARP and caspase-3.
Norgestrel (20 μM; 6 hours; 661W cells) treatment bFGF is results in a significant upregulation of bFGF mRNA in photoreceptor cells.
Cell Viability Assay
| Cell Line: | 661W cells |
| Concentration: | 20 μM |
| Incubation Time: | 24 hours |
| Result: | Significantly increased cellular viability after serum deprivation. |
Western Blot Analysis
| Cell Line: | 661W cells |
| Concentration: | 20 μM |
| Incubation Time: | 24 hours |
| Result: | Decreased apoptotic induced cleavage of PARP and caspase-3. |
RT-PCR
| Cell Line: | 661W cells |
| Concentration: | 20 μM |
| Incubation Time: | 6 hours |
| Result: | A significant upregulation of bFGF mRNA over 1 hour. |
Norgestrel (100 mg/kg; intraperitoneal injection; for 6, 24 or 48 hours; Balb/c mice) treatment can prevent light-induced ROS in photoreceptor cells, and subsequent cell death. Norgestrel acts via post-translational modulation of the major antioxidant transcription factor Nrf2; bringing about its phosphorylation, subsequent nuclear translocation, and increases levels of its effector protein superoxide dismutase 2 (SOD 2 ).
| Animal Model: | Balb/c mice are born into and maintained in dim cyclic light |
| Dosage: | 100 mg/kg; |
| Administration: | Intraperitoneal injection; for 6, 24 or 48 hours |
| Result: | Increased expression and activation of Nrf2 via phosphorylation on serine 40, increased expression of its target antioxidant superoxide dismutase 2 (SOD 2 ), and reduced mitochondrial oxidative stress. |
2. 用作探親避孕藥：于探親當(dāng)晚開始服炔諾孕酮探親避孕藥，每天1片，服法同炔諾酮。
3. 用作事后避孕藥：房事后72小時內(nèi)口服2片復(fù)方炔諾孕酮事后避孕片，12小時后再服2片。
2. 少見的有頭痛,胸、臀、腿特別是腓腸肌處疼痛,手臂和腳無力、麻木或疼痛,突然的或原因不明的呼吸短促，突然語言發(fā)音不清，突然視力改變、復(fù)視、不同程度失明等。
3. 長期應(yīng)用可引起肝功能異常，缺血性心臟病發(fā)生率上升，妊娠早期時應(yīng)用可能導(dǎo)致雄激素活性高引起的后代女嬰男性化以及生殖道畸形(多見為尿道下裂)。
2. 維生素C能增強(qiáng)口服避孕藥的作用，每天口服1g維生素C可使炔雌醇生物利用度從40%提高到60%～70%。
3. 與環(huán)孢素合用，可抑制環(huán)孢素的代謝清除，致其毒性增強(qiáng)，應(yīng)避免合用。